Genistein suppression of TNF-α-induced fractalkine expression in endothelial cells

Cellular Physiology and Biochemistry

Volumn 26, Issue 3, 2010, Pages 431-440

  Sung, Mi Jeong ^a   Kim, Duk Hoon ^b   Davaatseren, Munkhtugs ^a,c   Hur, Haeng Jeon ^a   Kim, Won ^b   Jung, Yu Jin ^b   Park, Sung Kwang ^b   Kwon, Dae Young ^a  

^a Korea Food Research Institute   (South Korea)

^b Chonbuk National University   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

Author keywords

Endothelial cells; Fractalkine; Genistein

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME REPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UMBILICAL VEIN;

EID: 78650019202     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320566     Document Type: Article

References (35)

1. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-644.
2. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature (Lond) 1997;387:611-617.
3. Harrison JK, Jiang Y, Wees EA, Salafranca MN, Liang HX, Feng L, Belardinelli L: Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999;66:937-944.
4. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon KB, Zerwes HG, Feng L: NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000;67:577-584.
5. Haskell CA, Cleary MD, Charo IF: Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000;275:34183-34189.
6. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-1419.
7. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-530.
8. Umehara H, Bloom E, Okazaki T, Domae N, Imai T: Fractalkine and vascular injury. Trends Immunol 2001;22:602-607.
9. Lesnik P, Haskell CA, Charo IF: Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003:111:333-340.
10. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM: A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-6072.
11. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P, Levy Y, Emilie D: Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 2001;98:1678-1686.
12. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, Miyasaka N: Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004;173:7010-1716.
13. Ahn SY, Cho CH, Park K G, Lee HJ, Lee S, Park SK, Lee IK, Koh G: Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Patho 2004;164:1663-1672.
14. Sung MJ, Kim W, Ahn SY, Cho CH, Koh GY, Moon SO, Kim DH, Lee S, Kang KP, Jang KY, Park SK: Protective effect of alpha-lipoic acid in lipopolysaccharide- induced endothelial fractalkine expression. Circ Res 2005;97:880-890.
15. Filipeanu CM, Brailoiu E, Huhurez G, Slatineanu S, Baltatu O, Branisteanu DD. Baltatu O, Branisteanu DD: Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Eur J Pharmacol 1995;281:29-35.
16. Messina M, Perskey V, Setchell KD, Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-131.
17. Fournier DB, Erdman Jr JW, Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomark Prev 1998;7:1055-1065.
18. Barnes S: Soy isoflavones-phystoestrogens and what else? J Nutr 2004;134:1225S-1228S.
19. Lee YW, Lee WH: Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells. J Nutr Biochem 2008;12:819-825.
20. Paradkar PN, Blum PS, Berhow MA, Baumann H, Kuo SM: Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett 2004;215:21-28.
21. Moon SO, Kim W, Sung MJ, Lee S, Kang KP, Kim DH, Lee SY, So JN, Park SK: Resveratrol suppresses tumor necrosis factor-induced fractalkine expression in endothelial cells. Mol Pharmacol 2006;70:112-129.
22. Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, Park SK: Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008;74:1538-1547.
23. + monocytes. J Exp Med 2003;197:1701-1707.
24. Anand AR, Bradley R, Ganju RK: LPS-induced MCP-1 expression in human microvascular endothelial cells is mediated by the tyrosine kinase, Pyk2 via the p38 MAPK/NF-kappaB-dependent pathway. Mol Immunol 2009;46:962-968.
25. Gutierrez-Ramos JC, Bluethmann H: Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunol Today 1997;18:329-334.
26. Oh DJ, Dursun B, He Z, Lu L, Hoke TS, Ljubanovic D, Faubel S, Edelstein CL: Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008;294:F264-271.
27. Campanile F, Giampietri A, Grohmann U, Belladonna ML, Fioretti MC, Puccetti P: Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in gram-negative sepsis. Eur J Pharmacol 1996;307:191-199.
28. Lee AS, Jung YJ, Kim DH, Lee TH, Kang KP, Lee S, Lee NH, Sung MJ, Kwon DY, Park SK, Kim W: Epigallocatechin-3- O-gallate decreases tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells by suppressing NF-kappaB. Cell Physiol Biochem 2009;24:503-510.
29. Lu H, Shi JX, Zhang DM, Chen HL, Qi M, Yin HX: Genistein, a soybean isoflavone, reduces the production of pro-inflammatory and adhesion molecules induced by hemolysate in brain microvascular endothelial cells. Acta Neurol Belg 2009;109:32-37.
30. Si H, Liu D: Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase. Apoptosis 2009;14:66-76.
31. Takano H, Yoshikawa T, Yamaguchi T, Hongo H, Fujii T, Boku Y, Yoshida N, Yamamoto H, Nakahashi Y, Yanagisawa R, Kondo M: Effects of aminoguanidine on systemic inflammatory response syndrome induced by platelet activating factor and by lipopolysaccharide in rats. Eur J Pharmacol. 1997;323:107-110.
32. Zhao JH, Arao Y, Sun SJ, Kikuchi A, Kayama F: Oral administration of soy-derived genistein suppresses lipopolysaccharide-induced acute liver inflammation but does not induce thymic atrophy in the rat. Life Sci 2006;78:812-819.
33. Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S: Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 1995;125:2307-2315.
34. Chang HC, Churchwell MI, Delclos KB, Newbold RR, Doerge DR: Mass spectrometric determination of genistein tissue distribution in diet-exposed Sprague-Dawley rats. J Nutr 2000;130:1963-1970.
35. Zhang Y, Hendrich S, Murphy PA: Glucuronides are the main isoflavone metabolites in women. J Nutr 2003;133:399-404.